Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 1

Безопасность амброксола в терапии респираторных заболеваний взрослых
С.Л. Бабак, М.В. Горбунова, А.Г. Малявин

References

1. Prevention of chronic bronchitis exacerbations with ambroxol (mucosolvan retard). An open, long-term, multicenter study in 5,635 patients. Respiration 1989;55(Suppl ):84-96.
2. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respiratory Care 2007 Sep;52(9):1176-93; discussion 1193-7.
3. Gupta PR. Ambroxol – resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. Lung India 2010 Apr;27(2):46-8.
4. de Mey C, Peil H, Kölsch S, Bubeck J, Vix JM. Efficacy and safety of ambroxol lozenges in the treatment of acute uncomplicated sore throat. EBM-based clinical documentation. Arzneimittelforschung 2008;58(11):557-68.
5. Chenot JF, Weber P, Friede T. Efficacy of ambroxol lozenges for pharyngitis: a meta-analysis. BMC Family Practice 2014 Mar;15:45.
6. de Mey C, Patel J, Lakha DR, Richter E, Kölsch S. Efficacy and safety of an oral ambroxol spray in the treatment of acute uncomplicated sore throat. Drug Research (Stuttgart) 2015 Dec;65(12):658-67.
7. European Medicines Agency (EMA). Pharmacovigilance Risk Assessment Committee (PRAC). Revised assessment report: ambroxol and bromhexine containing medicinal products, 2015. Available from: https://www.ema.europa.eu/en/documents/referral/ambroxol-bromhexine-article-31-referral-prac-assessment-report_en.pdf Accessed 2019 Jul 31.
8. Ambroxol, bromhexine: anaphylactic reactions. Prescrire International 2015 Apr;24(159):98.
9. UpToDate. Ambroxol: international drug information (concise), 2018. Available from: https://www.uptodate.com/contents/ambroxol-international-drug-information-concise Accessed 2019 Jul 31.
10. European Medicines Agency (EMA). Pharmacovigilance Risk Assessment Committee (PRAC). Ambroxol and bromhexine expectorants: safety information updated. Risk of allergy and skin reactions included in the product information, 2016. Available from: https://www.ema.europa.eu/en/documents/referral/ambroxol-bromhexine-article-31-referral-ambroxol-bromhexine-expectorants-safety-information-be_en.pdf Accessed 2019 Jul 31.
11. Seifart C, Clostermann U, Seifart U, Müller B, Vogelmeier C, von Wichert P, Fehrenbach H. Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicology and Applied Pharmacology 2005 Feb;203(1):27-35.
12. Takeda K, Miyahara N, Matsubara S, Taube C, Kitamura K, Hirano A, Tanimoto M, Gelfand EW. Immunomodulatory effects of ambroxol on airway hyperresponsiveness and inflammation. Immune Network 2016 Jun;16(3):165-75.
13. Disse BG, Ziegler HW. Pharmacodynamic mechanism and therapeutic activity of ambroxol in animal experiments. Respiration 1987;51(Suppl 1):15-22.
14. Akkoca Yildiz O. Ambroxol. Tüberküloz ve Toraks 2006;54(Suppl 1):3-14.
15. Zhang SJ, Jiang JX, Ren QQ, Jia YL, Shen J, Shen HJ, Lin XX, Lu H, Xie QM. Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1/2 signaling pathway. European Journal of Pharmacology 2016 Mar;775:138-48.
16. Kido H, Okumura Y, Yamada H, Mizuno D, Higashi Y, Yano M. Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential. Biological Chemistry 2004 Nov;385(11):1029-34.
17. Cataldi M, Sblendorio V, Leo A, Piazza O. Biofilm-dependent airway infections: a role for ambroxol? Pulmonary Pharmacology & Therapeutics 2014 Aug;28(2):98-108.
18. Guo Z, Chen Y, Ding X, Huang C, Miao L. Simultaneous determination of ambroxol and salbutamol in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. Biomedical Chromatography 2016 Nov;30(11):1789-95.
19. Couet W, Girault J, Reigner BG, Ingrand I, Bizouard J, Acerbi D, Chiesi P, Fourtillan JB. Steady-state bioavailability and pharmacokinetics of ambroxol and clenbuterol administered alone and combined in a new oral formulation. International Journal of Clinical Pharmacology, Therapy and Toxicology 1989 Sep;27(9):467-72.
20. Ni Y, Hou L, Chen L, Fan J. Bioequivalence assessment of ambroxol orally-disintegrating tablet after a single oral-dose administration to healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 2016 May;54(5):399-404.
21. Morice A, Kardos P. Comprehensive evidence-based review on European antitussives. BMJ Open Respiratory Research 2016 Aug;3(1):e000137.
22. Matthys H, de Mey C, Carls C, Ryś A, Geib A, Wittig T. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. Arzneimittelforschung 2000 Aug;50(8):700-11.
23. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. The Cochrane Database of the Systematic Reviews 2015 Jul;(7):CD001287.
24. Olivieri D, Zavattini G, Tomasini G, Daniotti S, Bonsignore G, Ferrara G, Carnimeo N, Chianese R, Catena E, Marcatili S, Del Donno M, Grassi C, Pozzi E, Grassi V, Tantucci C, Lucchesi M, Schimid G, Marchioni CF, Penitenti S, Mistretta A, Crimi N, Casali L, Cabiddu R, Donner C, Patessio A, Massei V, Sanguinetti CM, Orlandi O, Bruna S, Serra C, Giacopelli A. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration 1987;51(Suppl 1):42-51.
25. Cegla UH. Long-term therapy over 2 years with ambroxol (Mucosolvan) retard capsules in patients with chronic bronchitis. Results of a double-blind study of 180 patients. Praxis und Klinik der Pneumologie 1988 Sep;42(9):715-21.
26. Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulmonary Pharmacology & Therapeutics 2004;17(1):27-34.
27. Ericsson CH, Juhasz J, Jönsson E, Mossberg B. Ambroxol and simple chronic bronchitis. Effects on subjective symptoms and ventilatory function. Respiration 1987;51(Suppl 1):33-6.
28. Michnar M, Milanowski J. Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis. Pneumonologia i Alergologia Polska 1996;64(Suppl 1):90-6.
29. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opinion on Drug Metabolism & Toxicology 2008 Aug;4(8):1119-29.
30. Cazan D, Klimek L, Sperl A, Plomer M, Kölsch S. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opinion on Drug Safety 2018 Dec;17(12):1211-24.
31. Schulz M, Hämmerlein A, Hinkel U, Weis G, Gillissen A. Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study. International Journal of Clinical Pharmacology and Therapeutics 2006 Sep;44(9):409-21.
32. Boehringer Ingelheim GmbH. Internal study report U92-0575. 1992.
33. Saad N, Guillot I, Vautrin C, Freymond N, Catelain A, Kerhoas A, Nicolas JF. Ambroxol-induced toxicoderma. Annales de Dermatologie et de Vénéréologie 2006 Feb;133(2):181-2.
34. European PSUR Work Sharing Project (BE/H/PSUR/0003/001). Core safety profile: Ambroxol. Date of FAR 20.04.2010. Available from: https://www.bfarm.de/SharedDocs/Downloads/EN/Drugs/vigilance/PSURs/csp/a-b/ambroxol.pdf?__blob=publicationFile&v=3 Accessed 2019 Jul 31.
35. Kardos P, Beeh KM, Sent U, Mueck T, Gräter H, Michel MC. Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations. BMC Pharmacology and Toxicology 2018 Jul 4;19(1):40.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]